EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetics and Exposure‐Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors

Fang Yang, Yongying Lu, Lihui Bai, Chenhui Deng, Zhen Liu, Zhihua Sun, Li Li, Shicong Wang, Li Zhou, Haifeng Feng, Shaoyu Yan, Jiman Zhu

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Fang Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Gloria Biosciences Co.Ltd., Beijing, China. Hauptthemen laut MEDLINE: Neoplasms, Models, Biological, Dose-Response Relationship, Drug, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to establish a population pharmacokinetic (PopPK) model using data from 2 clinical trials of zimberelimab, evaluate the pharmacokinetics (PKs) of zimberelimab, explore the feasibility of 360 mg once every 3 weeks (Q3W) and 480 mg once every 4 weeks (Q4W) as alternative dosage regimens, and analyze the exposure‐response relationship of the efficacy and safety of zimberelimab for advanced tumors. The PKs of zimberelimab were described using the 2‐compartment model with time‐dependent nonlinear elimination. The prediction‐corrected visual predictive check was used to evaluate the model's predictive value on blood drug concentrations. In total, 2165 PK observations from 321 participants were included. The PopPK model demonstrated a high level of concordance between the observed data and the predicted values, indicative of a robust fit to the PK data of zimberelimab. The PK variables were similar for the 240 mg once every 2 weeks, 360 mg Q3W, and 480 mg Q4W regimens. No covariates significantly affecting the PK variables in the final model were found. The exposure variables of zimberelimab have no obvious correlations with efficacy and safety, and 360 mg Q3W and 480 mg Q4W are worthy of further study. This study establishes a PopPK model and analyzes the exposure‐response relationship of zimberelimab, which helps to explore the potential for alternative dosing regimens and offers a foundation for optimizing therapeutic strategies for advanced cancer patients through simulation‐based methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsModels, BiologicalDose-Response Relationship, DrugAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAdultAgedDrug Administration ScheduleAntineoplastic AgentsYoung AdultChinaEast Asian People

Stichwörter der Autor:innen

advanced tumorsdosage regimensexposure‐responsepopulation pharmacokineticzimberelimab

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents

Autor:innen und Institutionen

  • Guangzhou Gloria Biosciences Co.Ltd., Beijing, China.
  • Linking Truth Technology Co. Ltd., Beijing, China.
  • Department of Medical Affairs, Guangzhou Gloria Biosciences Co. Ltd., Beijing, China.
  • Department of Research and Development, Guangzhou Gloria Biosciences Co. Ltd., Beijing, China.

Zitieren

APA

Yang, F., Lu, Y., Bai, L., Deng, C., Liu, Z., Sun, Z., Li, L., Wang, S., Zhou, L., Feng, H., Yan, S., & Zhu, J. (2024). Population Pharmacokinetics and Exposure‐Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1439

Vancouver

Yang F, Lu Y, Bai L, Deng C, Liu Z, Sun Z, et al. Population Pharmacokinetics and Exposure‐Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1439

BibTeX
@article{Yang2024,
  author = {Yang, Fang and Lu, Yongying and Bai, Lihui and Deng, Chenhui and Liu, Zhen and Sun, Zhihua and Li, Li and Wang, Shicong and Zhou, Li and Feng, Haifeng and Yan, Shaoyu and Zhu, Jiman},
  title = {Population Pharmacokinetics and Exposure‐Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1439}
}
Kostenlos starten →